| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-92 |
Sentence |
denotes |
Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. |
| T2 |
93-242 |
Sentence |
denotes |
Despite widespread clinical use in the treatment of type 2 diabetes, the impact of sulfonylurea therapy on cardiovascular outcomes remains uncertain. |
| T3 |
243-382 |
Sentence |
denotes |
Studies of naturally occurring genetic variation can be used to anticipate the expected clinical consequences of a pharmacological therapy. |
| T4 |
383-654 |
Sentence |
denotes |
A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 p.A1369S) promotes closure of the target channel of sulfonylurea therapy and is associated with increased insulin secretion, thus mimicking the effects of sulfonylurea therapy. |
| T5 |
655-924 |
Sentence |
denotes |
Using individual-level data from 120,286 participants in the UK Biobank and summary association results from four large-scale genome-wide association studies, we examined the impact of this variant on cardiometabolic traits, type 2 diabetes, and coronary heart disease. |
| T6 |
925-1073 |
Sentence |
denotes |
The p.A1369S variant was associated with a significantly lower risk of type 2 diabetes (odds ratio [OR] 0.93; 95% CI 0.91, 0.95; P = 1.2 × 10(-11)). |
| T7 |
1074-1262 |
Sentence |
denotes |
The variant was associated with increased BMI (+0.062 kg/m(2); 95% CI 0.037, 0.086; P = 8.1 × 10(-7)) but lower waist-to-hip ratio adjusted for BMI, a marker of abdominal fat distribution. |
| T8 |
1263-1393 |
Sentence |
denotes |
Furthermore, p.A1369S was associated with a reduced risk of coronary heart disease (OR 0.98; 95% CI 0.96, 0.99; P = 5.9 × 10(-4)). |
| T9 |
1394-1550 |
Sentence |
denotes |
These results suggest that, despite a known association with increased weight, long-term sulfonylurea therapy may reduce the risk of coronary heart disease. |
